The National Health Insurance Administration (NHIA), the Center for Health Policy and Technology Assessment (CHPTA), and the UK’s National Institute for Health and Care Excellence (NICE) jointly held a third round of workshops on May 28 and 29 to promote health technology assessment collaboration between the two sides. The workshops focused on the design and execution of NICE's Cancer Drug Fund (CDF), as well as the data collection protocols and reassessment metrics used in the Managed Access Agreements (MAA).

The NHIA said that, starting January 1, 2025, NT$5 billion in central government funding has been allocated to National Health Insurance for the conditional reimbursement of new cancer drugs, with specifics of the earmark announced on February 25, 2025. The NHIA added that by learning from the UK’s experience with its CDF and MAA, Taiwan can enhance the conditional listing of new cancer drugs.

The NHIA stated that the CHPTA will develop techniques and train personnel in medical technology assessment, establish a value- and efficiency-based framework for drug reimbursement, and provide consultation on health policy assessment. The NHIA also said that a bill to establish the CHPTA as an incorporated administrative agency has been drafted.

[2025-5-28/ National Health Insurance Administration]